Sagent’s Haloperidol Injection receives FDA approval

SCHAUMBURG, Ill. (AP) — Earlier on Tuesday, Sagent Pharmaceuticals Inc. declared that an injectable version of the anti-psychotic drug has been approved by the US Food and Drug Administration. The generic version of Sagent’s drug is named haloperidol, the brand name of which is Haldol.

In the early fourth quarter, Sagent is expected to release single-and-multi-dose vials of the drug. According to estimates, injectable haloperidol is said to fetch nearly $12.5 million annually in the US market.

Haloperidol, which is available in both oral and injectable forms, is intended for treating patients with schizophrenia and Tourette syndrome.

Brushing aside a decline in the broader, Sagent shares jumped 17 cents to $20.36 on Tuesday.